Literature DB >> 21388488

Biased amplification of human papillomavirus DNA in specimens containing multiple human papillomavirus types by PCR with consensus primers.

Seiichiro Mori1, Sari Nakao, Iwao Kukimoto, Rika Kusumoto-Matsuo, Kazunari Kondo, Tadahito Kanda.   

Abstract

Genotyping human papillomavirus (HPV) in clinical specimens is important because each HPV type has different oncogenic potential. Amplification of HPV DNA by PCR with the consensus primers that are derived from the consensus sequences of the L1 gene has been used widely for the genotyping. As recent studies have shown that the cervical specimens often contain HPV of multiple types, it is necessary to confirm whether the PCR with the consensus primers amplifies multiple types of HPV DNA without bias. We amplified HPV DNA in the test samples by PCR with three commonly used consensus primer pairs (L1C1/L1C2+C2M, MY09/11, and GP5+/6+), and the resultant amplicons were identified by hybridization with type-specific probes on a nylon membrane. L1C1/L1C2+C2M showed a higher sensitivity than the other primers, as defined by the ability to detect HPV DNA, on test samples containing serially diluted one of HPV16, 18, 51, 52, and 58 plasmids. L1C1/L1C2+C2M failed to amplify HPV16 in the mixed test samples containing HPV16, and either 18 or 51. The three consensus primers frequently caused incorrect genotyping in the selected clinical specimens containing HPV16 and one or two of HPV18, 31, 51, 52, and 58. The data indicate that PCR with consensus primers is not suitable for genotyping HPV in specimens containing multiple HPV types, and suggest that the genotyping data obtained by such a method should be carefully interpreted.
© 2011 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21388488     DOI: 10.1111/j.1349-7006.2011.01922.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  22 in total

1.  Association between human papillomavirus and prostate cancer: A meta-analysis.

Authors:  Binbin Yin; Weiwei Liu; Pan Yu; Chunhua Liu; Yue Chen; Xiuzhi Duan; Zhaoping Liao; Yuhua Chen; Xuchu Wang; Xiaoyan Pan; Zhihua Tao
Journal:  Oncol Lett       Date:  2017-06-09       Impact factor: 2.967

2.  Evaluation of human papillomavirus type replacement postvaccination must account for diagnostic artifacts: masking of HPV52 by HPV16 in anogenital specimens.

Authors:  Joseph E Tota; Agnihotram V Ramanakumar; Luisa L Villa; Harriet Richardson; Ann N Burchell; Anita Koushik; Marie-Hélène Mayrand; François Coutlée; Eduardo L Franco
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-02       Impact factor: 4.254

3.  Invited commentary: multiple human papillomavirus infections and type replacement-anticipating the future after human papillomavirus vaccination.

Authors:  Mahboobeh Safaeian; Ana Cecilia Rodriguez
Journal:  Am J Epidemiol       Date:  2014-10-29       Impact factor: 4.897

4.  Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.

Authors:  Mélanie Drolet; Élodie Bénard; Norma Pérez; Marc Brisson
Journal:  Lancet       Date:  2019-06-26       Impact factor: 79.321

5.  Development of a novel liquid bead array human papillomavirus genotyping assay (PGMY-LX) and comparison with linear array for continuity in longitudinal cohort studies.

Authors:  Sepideh Farhat; Mark E Scott; Yifei Ma; Anna-Barbara Moscicki
Journal:  J Clin Microbiol       Date:  2015-02-04       Impact factor: 5.948

6.  Sequencing-based genotyping of mixed human papillomavirus infections by use of RipSeq software.

Authors:  Keith D Tardif; Keith E Simmon; Oyvind Kommedal; Michael T Pyne; Robert Schlaberg
Journal:  J Clin Microbiol       Date:  2013-01-30       Impact factor: 5.948

7.  Cervical Infection With Vaccine-Associated Human Papillomavirus (HPV) Genotypes as a Predictor of Acquisition and Clearance of Other HPV Infections.

Authors:  Joseph E Tota; Agnihotram V Ramanakumar; Luisa L Villa; Harriet Richardson; Ann N Burchell; François Coutlée; Eduardo L Franco
Journal:  J Infect Dis       Date:  2016-06-02       Impact factor: 5.226

8.  Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination.

Authors:  Joseph E Tota; Agnihotram V Ramanakumar; Mengzhu Jiang; Joakim Dillner; Stephen D Walter; Jay S Kaufman; François Coutlée; Luisa L Villa; Eduardo L Franco
Journal:  Am J Epidemiol       Date:  2013-05-09       Impact factor: 4.897

Review 9.  Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.

Authors:  Mélanie Drolet; Élodie Bénard; Marie-Claude Boily; Hammad Ali; Louise Baandrup; Heidi Bauer; Simon Beddows; Jacques Brisson; Julia M L Brotherton; Teresa Cummings; Basil Donovan; Christopher K Fairley; Elaine W Flagg; Anne M Johnson; Jessica A Kahn; Kimberley Kavanagh; Susanne K Kjaer; Erich V Kliewer; Philippe Lemieux-Mellouki; Lauri Markowitz; Aminata Mboup; David Mesher; Linda Niccolai; Jeannie Oliphant; Kevin G Pollock; Kate Soldan; Pam Sonnenberg; Sepehr N Tabrizi; Clare Tanton; Marc Brisson
Journal:  Lancet Infect Dis       Date:  2015-03-03       Impact factor: 25.071

10.  Next-generation sequencing of cervical DNA detects human papillomavirus types not detected by commercial kits.

Authors:  Tracy L Meiring; Anna T Salimo; Beatrix Coetzee; Hans J Maree; Jennifer Moodley; Inga I Hitzeroth; Michael-John Freeborough; Ed P Rybicki; Anna-Lise Williamson
Journal:  Virol J       Date:  2012-08-16       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.